Edition:
United States

OPKO Health Inc (OPK.O)

OPK.O on Nasdaq

6.71USD
22 Sep 2017
Change (% chg)

$0.23 (+3.55%)
Prev Close
$6.48
Open
$6.57
Day's High
$6.75
Day's Low
$6.44
Volume
7,434,932
Avg. Vol
4,439,195
52-wk High
$12.15
52-wk Low
$5.85

Latest Key Developments (Source: Significant Developments)

Opko Health CEO Phillip Frost​ buys 40,000 shares of co's common stock on Aug 16
Thursday, 17 Aug 2017 07:27am EDT 

Aug 17 (Reuters) - Opko Health Inc :Opko Health CEO Phillip Frost​ reports purchase of 40,000 shares of co's common stock on Aug 16 - SEC filing.  Full Article

Opko Health CEO Phillip Frost​ buys 25,000 shares of co's common stock on Aug 15
Wednesday, 16 Aug 2017 07:30am EDT 

Aug 16 (Reuters) - Opko Health Inc :Opko Health Inc <<>> CEO Phillip Frost​ reports purchase of 25,000 shares of co's common stock on Aug 15 - SEC filing.  Full Article

OPKO Health reports Q2 loss per share $0.04
Tuesday, 8 Aug 2017 04:15pm EDT 

Aug 9 (Reuters) - OPKO Health Inc -:OPKO Health reports second quarter 2017 business and financial results.Q2 revenue $314.2 million versus I/B/E/S view $322.6 million.OPKO Health Inc qtrly loss per share $0.04.  Full Article

Opko Health CEO Phillip Frost buys 50,000 shares of co's common stock on July 10
Tuesday, 11 Jul 2017 06:46am EDT 

July 11 (Reuters) - Opko Health Inc :Opko Health Inc CEO Phillip Frost reports purchase of 50,000 shares of co's common stock on July 10 - SEC filing.  Full Article

Xenetic Biosciences commences patient enrollment in phase 2 study evaluating XBIO-101 in conjunction with Progestin therapy for the treatment of endometrial cancer
Monday, 26 Jun 2017 08:35am EDT 

June 26 (Reuters) - Xenetic Biosciences Inc :Xenetic Biosciences commences patient enrollment in phase 2 study evaluating XBIO-101 in conjunction with Progestin therapy for the treatment of endometrial cancer.Xenetic Biosciences Inc- Patient dosing expected in Q3 2017.  Full Article

Opko Health says Genedx extended relationship with University Of California Health for genetic testing services​
Wednesday, 7 Jun 2017 08:00am EDT 

June 7 (Reuters) - Opko Health Inc :Opko Health Inc - ‍Genedx extended relationship with university of california health (uc health) for genetic, genomic, and molecular testing services​.  Full Article

OPKO Health provides commercial update for Rayaldee
Monday, 5 Jun 2017 11:17am EDT 

June 5 (Reuters) - OPKO Health Inc ::OPKO Health provides commercial update for Rayaldee.On track to reach 75% of insured lives by year end.Entered agreements with Medicare part D plan sponsors, and additional commercial insurance plans for reimbursement of Rayaldee​.Agreements entered expands percentage of insured lives with access to Rayaldee to approximately 68% as of June 1, 2017.  Full Article

Xenetic Biosciences reports Q1 loss per share $0.34
Tuesday, 16 May 2017 07:00am EDT 

May 16 (Reuters) - Xenetic Biosciences Inc -:Xenetic Biosciences reports 2017 first quarter financial results and provides business update.Xenetic Biosciences -on track to commence patient recruitment for lead product candidate xbio-101 for treatment of progestin resistant endometrial cancer.Xenetic Biosciences Inc qtrly loss per share $0.34.  Full Article

Opko Health reports quarterly loss per share $0.06
Tuesday, 9 May 2017 04:10pm EDT 

May 9 (Reuters) - Opko Health Inc ::Opko Health reports 2017 financial and operating results.Q4 revenue $296.1 million versus I/B/E/S view $310.8 million.Quarterly loss per share $0.06.  Full Article

Opko Health CEO reports purchase of 10,000 shares of co's common stock on May 5
Monday, 8 May 2017 07:01am EDT 

May 8 (Reuters) - Opko Health Inc :Opko Health Inc <<>> CEO Phillip Frost reports purchase of 10,000 shares of co's common stock on May 5 - SEC filing.  Full Article